Clinical Trials Logo

Advanced Ovarian Cancer clinical trials

View clinical trials related to Advanced Ovarian Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04862325 Recruiting - Clinical trials for Advanced Ovarian Cancer

SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS

SOPHIE
Start date: January 1, 2021
Phase: N/A
Study type: Interventional

The treatment of choice in advanced ovarian cancer is a cytoreductive surgery combined with chemotherapeutic treatment. This complex and aggressive surgery is associated with high postoperative complication rates that may result in a strong negative impact on the clinical results due to the delay with the start of adjuvant chemotherapy as well as the costs from the surgical process. Multimodal prehabilitation has emerged as an innovative intervention that focuses on optimizing physiological and psychological resilience to withstand the upcoming stress of surgery. It has been shown to reduce postoperative complications in major abdominal surgery, but has not been assessed yet in abdominal onco-gynecological surgery.

NCT ID: NCT04556539 Recruiting - Clinical trials for Advanced Ovarian Cancer

Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer

Start date: December 15, 2020
Phase: Phase 2
Study type: Interventional

A phase II, multicenter, open-label, single-arm study to evaluate the efficacy, safety and pharmacokinetics of SC10914 in subjects with gBRCA1/2 mutated advanced ovarian cancer in china.

NCT ID: NCT03878849 Recruiting - Clinical trials for Advanced Ovarian Cancer

Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®

PREDICT 2X-121
Start date: April 15, 2019
Phase: Phase 2
Study type: Interventional

This study is to be performed as an open label, multicenter, single arm study of 2X-121 to evaluate anti-tumor efficacy of 2X-121 as single agent therapy in a 28-days cycle in advanced ovarian cancer patients. 2X-121 will be supplied for oral administration once daily as 600 mg (3 x 200 mg) capsules in a 28 days cycle. Patients with predicted high likelihood of responding to the drug (2X-121) using drug response prediction (DRP®), will be included in the study.